Research programme: daptomycin/tedizolid

Drug Profile

Research programme: daptomycin/tedizolid

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Trius Therapeutics
  • Developer Cubist Pharmaceuticals
  • Class Cyclic peptides; Lipopeptides; Oxazolidinones
  • Mechanism of Action Cell wall inhibitors; Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA
  • 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
  • 11 Sep 2013 Trius Therapeutics has been acquired and merged into Cubist Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top